Asthma: Targeted Biological Therapies

This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the...

Full description

Saved in:
Bibliographic Details
Main Authors: Pelaia, Girolamo. (Author), Vatrella, Alessandro. (Author), Maselli, Rosario. (Author)
Corporate Author: SpringerLink (Online service)
Format: eBook
Language: English
Published: Cham : Springer International Publishing : Imprint: Springer, 2017.
Subjects:
ISBN: 9783319460079
Physical Description: VI, 99 p. 11 illus. in color. online resource.

Cover

Table of contents

LEADER 02840nam a22004215i 4500
001 101704
003 CZ-ZlUTB
005 20240914113551.0
006 m o d
007 cr nn 008mamaa
008 161112s2017 gw | s |||| 0|eng d
020 |a 9783319460079 
024 7 |a 10.1007/978-3-319-46007-9  |2 doi 
100 1 |a Pelaia, Girolamo.  |e author. 
245 1 0 |a Asthma: Targeted Biological Therapies /  |c by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2017. 
300 |a VI, 99 p. 11 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a počítač  |b c  |2 rdamedia 
338 |a online zdroj  |b cr  |2 rdacarrier 
506 |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty 
520 |a This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma. 
650 0 |a Medicine. 
650 0 |a Pharmacology. 
650 0 |a Allergy. 
650 0 |a General practice (Medicine). 
650 0 |a Respiratory organs  |x Diseases. 
650 0 |a Pediatrics. 
655 7 |a elektronické knihy  |7 fd186907  |2 czenas 
655 9 |a electronic books  |2 eczenas 
700 1 |a Vatrella, Alessandro.  |e author. 
700 1 |a Maselli, Rosario.  |e author. 
710 2 |a SpringerLink (Online service) 
776 0 8 |i Printed edition:  |z 9783319460055 
856 4 0 |u https://proxy.k.utb.cz/login?url=http://dx.doi.org/10.1007/978-3-319-46007-9  |y Plný text 
992 |c NTK-SpringerMED 
999 |c 101704  |d 101704 
993 |x NEPOSILAT  |y EIZ